<![CDATA[Coronavirus: clinical trial begins on third vaccine candidate in China]>
A clinical trial has begun on a third potential coronavirus vaccine in China, where the first cases of the deadly virus strain were detected late last year.
According to researchers involved in the latest trial, "tens of volunteers" in Xuzhou, Jiangsu province were given the vaccine candidate on Thursday and it had already shown "positive results".
Developed by a team led by Qin Chuan at the National Institutes for Food and Drug Control in Beijing, it targets the initial strain of the virus and other mutations that have emerged as it has spread around the world.
Preclinical tests on non-human primates found that the potential vaccine, when given at a sufficient dose, could provide "complete protection against Sars-CoV-2" strains in different countries with minimal side-effects, Qin and his team wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday. Sars-CoV-2 refers to the virus that causes Covid-19.
Mutation is a big concern for doctors and scientists racing to develop a vaccine for the coronavirus. Those being developed target specific genes in the virus, but as the pandemic has swept the globe, it has mutated into different strains.
So far, more than 4,300 mutations of the new coronavirus have been detected worldwide by Chinese scientists, and some have warned that its ability to mutate has been vastly underestimated. As new strains emerge, it also adds to the challenge for scientists developing vaccines.
Qin's team based their potential vaccine on a strain isolated from a patient in Zhejiang. The province in eastern China has not been badly hit by the virus compared to other places " it has a population of nearly 60 million, but has reported about 1,200 cases and one death.
They then sought to test whether a vaccine based on this strain would work on others. According to their paper, the team analysed the whole genome sequence of the coronavirus in a global database, identifying major clusters of mutated strains across the world. They then isolated the strains that had the most typical mutations, based on 10 recently infected patients from China, Italy, Britain, Switzerland and Spain.
Tests on macaques had encouraging results " they developed antibodies to a level equivalent to those infected by the virus, the researchers said. The vaccinated macaques were then given "strains circulating worldwide" but the pathogens did not affect them, according to the paper.
The vaccine candidate's safety and effectiveness is now being put to the test in human trials, but there is also the question of whether it can provide immunity for multiple strains.
The team did not have a strain from a patient in the United States, for instance, so instead used one from a Chinese patient that had a mutation similar to those prevalent in North America. The researchers also noted that they had not included new mutations from less reported areas including Latin America, the Middle East and India.
Qin did not immediately respond to a request for comment.
One of the study authors, Gong Xuejie from Sinovac Biotech, a Beijing-based company involved in the project, said the first volunteers in the trial were all healthy adults aged between 18 and 59.
"Safety checks on the first day after the vaccinations have been completed and preliminary results show the vaccine [candidate] is safe," Gong told Shanghai news website Thepaper.cn on Friday.
She said two more clinical trials would follow and they would be larger scale and include children and elderly people but there was "no definite schedule".
A volunteer receives a shot as part of another clinical trial in Wuhan last week. Photo: DPA alt=A volunteer receives a shot as part of another clinical trial in Wuhan last week. Photo: DPA
The potential vaccine is one of at least five being developed in China, and it is estimated that more than 70 are being developed around the world. Two other vaccine candidates are being tested on humans in China, and at least two more are undergoing clinical trials in the United States.
Experts say a vaccine could still be more than a year away, but a Chinese health official on Monday said the government may consider approving one earlier for emergency use.
Gao Fu, director of the Chinese Centre for Disease Control and Prevention, told official newspaper Beijing Daily that if the pandemic worsened, a vaccine candidate "may be given to some people at the end of the year, such as medical personnel".
"This must be for use in an emergency situation, not for ordinary healthy people," Gao said.
Sign up now and get a 10% discount (original price US$400) off the China AI Report 2020 by SCMP Research. Learn about the AI ambitions of Alibaba, Baidu & JD.com through our in-depth case studies, and explore new applications of AI across industries. The report also includes exclusive access to webinars to interact with C-level executives from leading China AI companies (via live Q&A sessions). Offer valid until 31 May 2020.
This article originally appeared on the South China Morning Post (SCMP).
Copyright (c) 2020. South China Morning Post Publishers Ltd. All rights reserved.
